More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

CVS stock surges nearly 50% in 2025, aided by strong Q1 results, raised guidance and easing Medicare regulation risks.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

U.S. Reps. Raja Krishnamoorthi, D-Ill., and Earl “Buddy” Carter, R-Ga., along with nine other representatives, introduced a ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Cigna's announcement follows CVS Caremark designating Wegovy as its preferred weight loss drug last month.

Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success.

Last month, CVS Caremark announced that it had struck a deal to make Novo's Wegovy its primary weight loss drug starting in the second half of the year, which would mean coverage for Lilly's ...